Welcure drugs & pharmaceuticals Limited has submitted its mandatory confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to the Bombay Stock Exchange. The filing covers the fourth quarter and annual year ended March 31, 2026, representing a key regulatory compliance requirement for listed companies.

Regulatory Compliance Details

The certificate was submitted on April 3, 2026, and confirms that no physical share certificates were received for dematerialization of securities from the depository participant during the specified period. This certification is issued by the company's Registrar and Transfer Agent, Skyline Financial Services Pvt Ltd, and serves as confirmation of compliance with SEBI's depositories regulations.

Company Information

Welcure Drugs & Pharmaceuticals Limited operates from its registered office located at Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi. The company is incorporated under CIN: L68100DL1996PLC227773 and maintains its corporate website at welcure.co.in.

Certification Process

The confirmation certificate was signed by Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, on April 1, 2026. The document specifically states that no physical share certificates were received for dematerialization of equity shares during the quarter ended March 31, 2026. This certification process ensures transparency in the company's share transfer and dematerialization activities.

Management Authorization

The submission to BSE was authorized by Chintan Didawala Ganpat, Managing Director and CFO of Welcure Drugs & Pharmaceuticals Limited, with DIN: 11088268. The digital signature was applied on April 3, 2026, at 15:15:30 +05'30', confirming the authenticity of the regulatory filing. This demonstrates the company's commitment to maintaining proper corporate governance and regulatory compliance standards.

Welcure Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, showcasing notable operational performance during the period. The company's Board of Directors approved these results during their meeting held on February 12, 2026, at the registered office in New Delhi.

Financial Performance Overview

The pharmaceutical company reported mixed quarterly results with significant operational shifts compared to previous periods. The financial metrics demonstrate the company's evolving business focus and operational adjustments.

Nine-Month Performance Highlights

The company demonstrated strong cumulative performance for the nine months ended December 31, 2025, significantly outperforming the corresponding period in the previous year.

Segment-wise Analysis

The company operates in two primary business segments: Agriculture and Drugs & Pharmaceuticals. During Q3FY26, the agriculture segment contributed the entire revenue, while the pharmaceutical segment showed no activity.

Agriculture Segment Performance:

• Q3FY26 revenue: ₹146.43 lakhs
• Segment assets: ₹19522.94 lakhs
• Operating results (EBITDA): ₹142.55 lakhs

Drugs & Pharmaceuticals Segment:

• Q3FY26 revenue: ₹0 lakhs
• Previous quarter activity showed strong performance in pharmaceutical operations

Operational Metrics and Capital Structure

The company's paid-up equity share capital increased significantly to ₹12359.40 lakhs in Q3FY26 from ₹1125.12 lakhs in the previous quarter, indicating substantial capital restructuring. Total expenses for the quarter were ₹3.88 lakhs, primarily comprising employee benefits expense of ₹1.94 lakhs and other expenses of ₹1.44 lakhs.

Auditor's Review and Compliance

The financial results underwent limited review by statutory auditors Sarang Shivajirao Chavan and Associates, Chartered Accountants. The auditors issued their review report in accordance with Standard on Review Engagements (SRE) 2410, confirming compliance with Indian Accounting Standards and SEBI listing regulations.

The results were prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015, and comply with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Source: